Omnicell (NASDAQ:OMCL) Stock Rating Lowered by Zacks Research

Omnicell (NASDAQ:OMCL) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Piper Sandler reissued an “overweight” rating and set a $49.00 price target (down previously from $63.00) on shares of Omnicell in a research note on Friday. Wall Street Zen downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday. Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target on the stock in a research note on Wednesday, February 4th. Benchmark increased their price objective on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Finally, UBS Group set a $53.00 target price on shares of Omnicell in a research report on Friday, January 16th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and an average target price of $54.29.

Omnicell Trading Up 6.8%

Shares of OMCL stock opened at $39.00 on Monday. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 975.24, a PEG ratio of 1.21 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. The firm has a 50-day moving average price of $46.24 and a 200 day moving average price of $37.24. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). The firm had revenue of $313.98 million for the quarter, compared to analyst estimates of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Research analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.52% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently bought and sold shares of the company. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Omnicell in the fourth quarter valued at $527,000. State of Wyoming increased its holdings in shares of Omnicell by 162.0% in the 4th quarter. State of Wyoming now owns 14,172 shares of the company’s stock worth $642,000 after acquiring an additional 8,762 shares during the period. Geode Capital Management LLC lifted its position in Omnicell by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock valued at $51,088,000 after purchasing an additional 11,424 shares during the last quarter. Jackson Creek Investment Advisors LLC acquired a new position in Omnicell during the 4th quarter valued at about $2,022,000. Finally, Clearstead Advisors LLC boosted its stake in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.